// Case study
QDX
Public Relations
QDX is a quantum chemistry software company founded in 2021 that is redefining how the pharmaceutical and materials science industries approach molecular simulation. Their flagship product, EXESS, is a GPU-accelerated quantum chemistry engine that runs 1,000x faster than previous methods — fast enough to put high-resolution quantum chemistry simulations in the hands of everyday researchers. They also developed Rush, an LLM-first drug discovery platform built on quantum chemistry, and won the prestigious Gordon Bell Prize for their advances in supercomputing.
Despite groundbreaking technology and meaningful scientific achievements, QDX had a visibility problem. The company had made significant breakthroughs in AI-driven drug discovery and quantum chemistry simulation but had not translated that progress into the kind of media coverage that attracts pharmaceutical partnerships. As a research-focused startup competing for attention in a crowded AI and biotech landscape, QDX needed to move beyond academic circles and establish itself as a recognized name among the pharma executives, business development teams, and investors who drive partnership decisions.
With the JPMorgan Healthcare Conference approaching — the industry’s most important dealmaking event — the window to build that profile was narrow and the stakes were high.
Digital Elevator developed a PR strategy focused on turning QDX’s scientific depth into compelling media narratives that would resonate with both technical and business audiences.
The core challenge was bridging the gap between QDX’s highly technical quantum chemistry work and the language that editors and reporters at major publications respond to. We worked with the QDX team to distill their technology into clear, story-worthy angles: the speed advantage of EXESS over legacy methods, the real-world drug discovery applications, and the broader implications of making quantum chemistry accessible to researchers who previously couldn’t use it.
We developed a thought leadership strategy positioning QDX’s team as authoritative voices in the quantum chemistry and AI drug discovery space. This included securing guest bylines and in-depth feature articles in key science and technology publications, establishing the kind of editorial credibility that compounds over time.
Ahead of the JPMorgan Healthcare Conference, we executed a targeted media outreach campaign to secure interviews and coverage that would put QDX in front of the right audience at the right moment. The goal was to ensure that when pharma business development teams were researching potential partners before and during JPMorgan, QDX would already be part of the conversation.
Rather than concentrating placements in a single vertical, we pursued coverage across a diverse set of outlets — from pharma trade publications to mainstream science media to enterprise technology press. This multi-channel approach ensured QDX’s story reached pharmaceutical decision-makers, academic researchers, and technology-focused investors alike.
In just three months, Digital Elevator secured over 10 earned media placements for QDX across high-authority science, pharma, and technology publications. The coverage established QDX as a credible, visible player in the AI-driven drug discovery space — exactly the kind of profile that facilitates the pharmaceutical partnerships QDX set out to build.
What impressed us most was how quickly Digital Elevator understood our technology and translated it into stories that resonated with non-technical audiences. As a small team, we didn't have the bandwidth or media relationships to do this ourselves. They made the process effortless and the results spoke for themselves.
Every case study started with a conversation. Tell us about your goals and we will show you what we can do.
3-day turnaround guaranteed. 100% money-back guarantee on every product.